Genesis Pharma S.A.

GENESIS Pharma's strong track record of building long-standing partnerships with some of the leading multinational biopharmaceutical companies has been a key factor in the company's success. The company has entered into agreements with the following companies for the sale and marketing of biopharmaceutical products:

Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, using its proprietary ribonuclease (RNase) technology platform.

Amgen, the world's largest biotechnology company, discovers, develops, manufactures and markets important human therapeutics based on advances in cellular and molecular biology and medicinal chemistry.

Biogen Idec Inc. was created in 2003 by merging two of the world's leading biotech companies: Biogen Inc. and IDEC Pharmaceuticals Corporation. The merger fused the complementary capabilities of both companies in therapeutic focus, R&D and manufacturing, global infrastructure and financial strength. Biogen Idec is dedicated to creative science and intends to pursue growth by discovering, developing, manufacturing and selling original products and through strategic alliances by becoming the partner-of-choice in biologics development. Product and development programmes address a variety of key medical needs in oncology, neurology, dermatology and rheumatology.

www.biovitrum.com

Biovitrum is a Swedish pharmaceutical company. The company markets a range of specialist pharmaceuticals internationally. Using its expertise and experience Biovitrum takes scientific innovation all the way to the market and to specialist indication patients with significant medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases and malabsorption. The company has revenues of approximately SEK 1.2 billion and around 400 employees. It is listed on the OMX Nordic Exchange in Stockholm.

CellSeed is a biotechnology innovator focused on novel surface and cell culture products. CellSeed is dedicated to provide promising and innovative solutions for tissue-engineering through development of novel cell harvest methods and 3-dimensional living tissue replacement products for "Cell-sheet therapy" and regenerative medicine to improve human quality of life.

A CellSeed's regenerative living cornea epithelial cell-sheet is currently under clinical development for the treatment of Limbal Stem Cell Deficiency (LSCD), which results in persistent epithelial breakdown, superficial corneal vascularization, chronic discomfort and impaired vision. The unique regenerative medicine technique developed by CellSeed and its collaborator, the Tokyo Women's Medical University called "Cell-sheet engineering" avoids the problems of donor shortage, graft-versus-host disease and transplant rejection and the need of sutures for engraftment.

Cephalon specializes in drugs to treat and manage neurological diseases; sleep disorders, cancer and pain, and is one of the world's fastest-growing biopharmaceutical companies. With 2100 employees, an expanded international presence with operations in the United States and Europe, and a diverse product portfolio, Cephalon is poised for continued growth. From researching target molecules to advancing late-stage compounds, Cephalon contributes to scientific understanding, while preparing a new portfolio of treatments.

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.

Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. Established in 1995 and ranked among the top-20 U.S. pharmaceutical companies (based on retail sales), Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with fiscal year 2007 (year ended March 31, 2008) sales of approximately $3 billion, including the results of the acquisition of MGI PHARMA, INC.

www.idm-pharma.com

IDM Pharma is a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer. IDM is currently developing two types of products: the first is designed to destroy cancer cells by activating innate immunity, and the second to prevent tumor recurrence by triggering a specific adaptive immune response.

IDM Pharma currently has 5 products in clinical development in oncology. The most advanced product has completed a Phase III clinical trial in oncology and the rest products are in Phase II and I, in oncology as well. IDM Pharma has a major product development partnership with SANOFI-AVENTIS in cancer immunotherapy. MEDAREX and SANOFI-AVENTIS are corporate partners and shareholders of IDM or its affiliate since 1993 and 2001, respectively.

PharmaMar is the world leader biopharmaceutical company of the Zeltia Group, committed to advancing the treatment of cancer through the discovery and development of new marine-derived medicines. PharmaMar's headquarters are in Madrid (Spain) and laboratories in Cambridge (US).

Pharmamar was founded in 1986, with the vision of exploiting the great potential of the oceans as a source of novel medicines for improved cancer treatment. PharmaMar has a unique collection of 55,000 marine organisms obtained from expeditions around the world. 700 new chemical entities have been discovered and 30 new families of compounds have been identified. PharmaMar also has a rich pipeline of preclinical candidates, and a strong R&D program.

www.shire.com

Founded in 1986, Shire Pharmaceuticals Group plc is a global specialty pharmaceutical company marketing products to specific customer groups. Shire's research and development focus is on late stage projects in areas where the company has a commercial presence. Sales and marketing is a core Shire competence, where a relatively small but high quality sales force is able to maximise sales by effective targeting. Shire avoids involvement in the highest risk area of discovery research for small molecules or research into genomics, combining investment in product development with careful attention to risk management.

Vifor (International) Inc. is the world leader in the market for pharmaceutical iron products. Based in St. Gallen, in the North-Eastern part of Switzerland, the company supplies distributors or licensees in around 80 countries with active compounds and oral and parenteral iron products. Vifor (International) Inc. focuses on its core competencies of developing, producing and marketing pharmaceutical iron products